Tango Therapeutics Inc (NASDAQ:TNGX), a clinical-stage biotechnology company, announced on Wednesday that the US Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for TNG462, a next-generation methylthioadenosine-cooperative (MTA) inhibitor of protein arginine methyl transferase 5 (PRMT5) for the treatment of cancers with methylthioadenosine phosphorylase (MTAP) deletion.
The company expects to initiate a Phase 1/2 clinical trial of TNG462 in mid-2023. This trial will involve patients with an MTAP deletion and will evaluate cancers including non-small cell lung cancer, mesothelioma and cholangiocarcinoma.
Tango Therapeutics also reported that the FDA has granted Orphan Drug Designation (ODD) to TNG908 for the treatment of malignant glioma.
TNG908, an MTA-cooperative PRMT5 inhibitor designed to selectively kill cancer cells with MTAP deletions, is currently being evaluated in a Phase 1/2 clinical trial.
TNG462 has the same mechanism of action as TNG908 with enhanced potency and selectivity in MTAP-deleted xenograft models, Tango Therapeutics explained. In preclinical studies, TNG462 is 45X selective for MTAP-deletions (3-fold greater than TNG908) and 20 times more potent than TNG908, which may provide a wider therapeutic index and stronger target inhibition than TNG908.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration